Last reviewed · How we verify
Riboflavin+UV RBC
Riboflavin combined with ultraviolet (UV) light exposure inactivates pathogens in red blood cells to reduce transfusion-transmitted infections.
Riboflavin combined with ultraviolet (UV) light exposure inactivates pathogens in red blood cells to reduce transfusion-transmitted infections. Used for Reduction of transfusion-transmitted infections in red blood cell products, Pediatric hematologic disorders requiring transfusion support.
At a glance
| Generic name | Riboflavin+UV RBC |
|---|---|
| Sponsor | Federal Research Institute of Pediatric Hematology, Oncology and Immunology |
| Drug class | Pathogen reduction technology / Blood product treatment |
| Modality | Biologic |
| Therapeutic area | Hematology / Transfusion Medicine |
| Phase | Phase 3 |
Mechanism of action
This is a pathogen reduction technology (PRT) for blood products. Riboflavin (vitamin B2) acts as a photosensitizer that, when activated by UV-A or UV-B light, generates reactive oxygen species that damage nucleic acids in pathogens (bacteria, viruses, parasites) and inactivate them while minimizing damage to RBC viability and function. The treated blood product retains adequate hemoglobin function for transfusion while reducing infectious disease transmission risk.
Approved indications
- Reduction of transfusion-transmitted infections in red blood cell products
- Pediatric hematologic disorders requiring transfusion support
Common side effects
- Hemolysis or reduced RBC viability
- Transfusion reactions
Key clinical trials
- Clinical Use of Pathogen Reduced Red Blood Cell Suspension (PHASE3)
- Inactivation of Whole Blood With Mirasol (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: